Medical, legal, and regulatory (MLR) review processes are under strain as pharmaceutical companies face pressure to produce more content on more channels.
What was once a structured, linear workflow is now Dynamic, cross-functional processes It involves medical, legal, regulatory, and commercial stakeholders, often working simultaneously across multiple brands, geographies, and timelines.
However, many MLR platforms have not kept pace with this change.
Instead, organizations often find themselves working internally. Rigorous systems that require teams to adapt processes to technologyrather than the other way around.
This growing mismatch is driving new priorities across the industry, including: Flexibility.
Rigid workflows create friction between MLR teams
Traditional promotion review platforms are built around predefined workflows, including fixed stages, fixed roles, and limited ability to adapt as an organization’s needs evolve.
In practice, this rigidity can lead to challenges such as:
- Delays caused by inflexible approval pathways
- Limited ability to adjust workflow by brand or treatment area
- Friction between cross-functional stakeholders
- Difficulty scaling processes as the organization grows
Managing these limitations can become increasingly difficult, especially for emerging biotech companies and mid-sized pharmaceutical companies.
As review processes evolve, many teams are starting to realize that: Flexibility is no longer a “nice-to-have”; it is essential to operational efficiency.
ERMA evaluation Built with flexibility in mind from the ground up
ERMA Evaluate was designed to reflect how MLR teams actually work, rather than how legacy systems expect them to behave.
At the core of the platform, Fully configurable workflow This allows organizations to define their own review structures across medical, legal, regulatory, and commercial functions.
ERMA Evaluate enables teams to:
- Customize review stages based on your internal governance model
- Dynamically assign roles and responsibilities
- Adapt workflows across brands, geographies, and asset types
- Change processes as regulatory expectations evolve
This flexibility allows ERMA Evaluate to support organizations at various stages of growth, from biotech startups establishing their first MLR process to established pharmaceutical companies managing complex multi-brand portfolios.
Rather than forcing standardization, ERMA evaluation Align with your team’s existing way of working.
Flexibility extends beyond workflow to the entire review experience
In many systems, workflow flexibility is limited to surface-level configuration.
ERMA Evaluate takes a broader approach that incorporates flexibility throughout the review lifecycle.
This includes:
- Content review: Supports a wide range of asset types including documents, presentations, and multimedia
- collaboration: Enable cross-functional teams to interact within a shared, centralized environment
- Traceability: Maintain visibility into how content progresses through the review process
- Regulatory compliance: Organize approved materials for submission and audit
By extending flexibility beyond just workflow configuration, ERMA Evaluate helps ensure that every part of the review process adapts to the changing needs of your organization.
AI supports flexibility by adapting to content rather than predefined systems
A key factor enabling this flexibility is ERMA Evaluate’s use of artificial intelligence.
Rather than relying on predefined structures that require ongoing maintenance, ERMA’s AI directly analyzes promotional materials, helps identify claims within content, and assists in assigning references within workflows.
This approach eliminates the need for teams to fit content into predefined frameworks and allows the platform to adapt to each asset under review.
For the MLR team, this means:
- Reduce time spent managing support systems
- More emphasis on evaluating the content itself
- Improved coordination between workflow and actual review behavior
In this way, ERMA’s AI enhances flexibility, rather than restricting it.
A more adaptable model to the changing regulatory environment
The regulatory landscape continues to evolve, increasing scrutiny of promotional materials and increasing complexity in how content is developed and distributed.
In this environment, organizations need systems that: Adapt quickly without requiring major reconfiguration or process redesign.
ERMA Evaluate provides that adaptability.
ERMA Evaluate combines configurable workflows, AI-driven content analysis, and unified document management to enable teams to respond to changing requirements without creating additional operational burden.
Flexibility defines the future of MLR technology
That shift is becoming apparent as life sciences companies modernize their promotion review processes.
The next generation of MLR platforms will not be defined solely by automation or AI, but by their capabilities. Adapt to the organizations that use them.
ERMA Evaluate represents this change.
ERMA Evaluate is helping life sciences teams move to a more efficient, scalable, and resilient model for MLR reviews by prioritizing flexibility, content review, and regulatory compliance across the workflow while reducing reliance on rigid systems.
Start your ERMA Evaluate trial.
www.ermasystems.com/trial
